Keywords: Pfizer, Tafamidis, USA, FDA, Polyneuropathy, TTR-FAP, Vyndaqel, CRL

US FDA calls for more efficacy data on Pfizer's tafamidis NDA

Article | 19 June 2012

Print This

The US Food and Drug Administration yesterday issued a complete response letter regarding drugs behemoth Pfizer’s (NYSE: PFE) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in